Ultromics - Life Sciences Executive Search & Team Build

About Ultromics

Ultromics is a medical technology company specialising in precision diagnostics for heart failure. Its AI-powered platform, EchoGo®, combines artificial intelligence with cardiac ultrasound to support clinicians in making more precise and efficient assessments.

Built using one of the largest known heart disease datasets in echocardiography, Ultromics’ technology focuses on challenging cardiac conditions, including heart failure with preserved ejection fraction (HFpEF), with the aim of supporting earlier diagnosis and intervention.

Reason and Purpose

Ross Upton founded Ultromics while working in the cardiac echo group at the John Radcliffe Hospital in Oxford. The company has developed from initial concept to achieve European CE marking and multiple US FDA clearances, and has established pivotal clinical partnerships with world-renowned medical institutions. Financing from Oxford Science Innovation (OSI) and world-class investors has supported rapid growth on a pan-geographic basis.

Ultromics is changing how physicians detect and diagnose heart failure, using novel AI-based applications and partnering with leading clinical and corporate groups to demonstrate the power of the technology. Building the right leadership team was central to that ambition.

Search Process and Methodology

Compass Carter Osborne’s Life Sciences Practice Director, Chris Coe, was involvement began at the very outset of the organisation, when he introduced Helen Routh, who went on to become Chairman. His insight into organisational design then supported Ross’s growing vision through the early phase of the company’s growth.

Working closely with the Founder, the Chairman and the new leadership hires, CCO through Chris helped ensure Ultromics was well positioned for additional funding rounds and the achievement of key milestones. He was also able to make introductions to key media players in the early-stage medical device world, which generated valuable early coverage and helped build a following for the technology within the med-tech innovation community.

Outcome

Following the placement of Helen Routh as Chairman, CCO continued to support Ultromics’ talent growth through executive search for a series of senior appointments:

• Chief Operating Officer
• Chief Financial Officer
• Chief Commercial Officer
• Head of Product Development
• VP International

Business outcomes: Ultromics raised seed funding from Oxford Science Innovation, and founder Ross Upton’s vision for an echocardiography system capable of predicting disease and patient outcomes has been realised through multiple additional funding rounds and regulatory milestones.

Meet the Life Sciences executive search contact

Chris Coe, Director, Life Sciences Practice

Chris is a Director in the Life Sciences Practice at Compass Carter Osborne (CCO), with more than two-and-a-half decades of experience delivering executive appointments into the global life sciences industry.

His background ranges from early-stage venture capital-backed life science start-ups through to global private equity-backed pharmaceutical and medtech companies. This extensive network of industry leaders has been strengthened by his depth of partnership within the corporate pharmaceutical, medtech and life science tools arena.

Email: [email protected]  |  Telephone: +44 (0) 208 036 6530